133 related articles for article (PubMed ID: 6702135)
41. Prolactin and breast cancer risk.
Tworoger SS; Hankinson SE
Cancer Lett; 2006 Nov; 243(2):160-9. PubMed ID: 16530327
[TBL] [Abstract][Full Text] [Related]
42. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
43. Comparative study of blood insulin levels in breast and endometrial cancer patients.
Gamayunova VB; Bobrov YuF ; Tsyrlina EV; Evtushenko TP; Berstein LM
Neoplasma; 1997; 44(2):123-6. PubMed ID: 9201292
[TBL] [Abstract][Full Text] [Related]
44. Patterns of surgical treatment for women diagnosed with early breast cancer in Queensland.
Thompson B; Baade P; Coory M; Carrière P; Fritschi L
Ann Surg Oncol; 2008 Feb; 15(2):443-51. PubMed ID: 17909915
[TBL] [Abstract][Full Text] [Related]
45. The basal and TRH stimulated levels of prolactin in low risk climacteric patients with increased breast density: a matched pair case control trial.
Soysal S; Soysal ME; Karabulut N; Gul N; Gezgin T
Maturitas; 2006 May; 54(2):103-9. PubMed ID: 16530361
[TBL] [Abstract][Full Text] [Related]
46. Increased risk for cancer of the breast due to previous medication.
de Levin RW; Puig OR; Levin E
Arch Geschwulstforsch; 1984; 54(2):153-8. PubMed ID: 6732438
[TBL] [Abstract][Full Text] [Related]
47. [Prolactin. Radioimmunoassay in female breast cancers and benign mastopathies].
Gorins A; Netter A
Nouv Presse Med; 1974 Jan; 3(2):73-5. PubMed ID: 4815434
[No Abstract] [Full Text] [Related]
48. Development and trends of surgical modalities for breast cancer in China: a review of 16-year data.
Yu KD; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Ann Surg Oncol; 2007 Sep; 14(9):2502-9. PubMed ID: 17564750
[TBL] [Abstract][Full Text] [Related]
49. [Phospholipid composition of blood lipids in breast and uterine cancer].
Kotrikadze NG; Tsartsidze MA; Dzhishkariani OS; Londaridze AM; Lomsadze BA
Eksp Onkol; 1987; 9(2):68-70. PubMed ID: 3582245
[TBL] [Abstract][Full Text] [Related]
50. Association of surgery with improved survival in stage IV breast cancer patients.
Blanchard DK; Shetty PB; Hilsenbeck SG; Elledge RM
Ann Surg; 2008 May; 247(5):732-8. PubMed ID: 18438108
[TBL] [Abstract][Full Text] [Related]
51. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.
Sancak B; Coskun U; Gunel N; Onuk E; Cihan A; Karamercan A; Yildirim Y; Ozkan S
Intern Med J; 2004 Jun; 34(6):310-5. PubMed ID: 15228391
[TBL] [Abstract][Full Text] [Related]
52. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem?
Sacchini V; Pinotti JA; Barros AC; Luini A; Pluchinotta A; Pinotti M; Boratto MG; Ricci MD; Ruiz CA; Nisida AC; Veronesi P; Petit J; Arnone P; Bassi F; Disa JJ; Garcia-Etienne CA; Borgen PI
J Am Coll Surg; 2006 Nov; 203(5):704-14. PubMed ID: 17084333
[TBL] [Abstract][Full Text] [Related]
53. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
Babiera GV; Rao R; Feng L; Meric-Bernstam F; Kuerer HM; Singletary SE; Hunt KK; Ross MI; Gwyn KM; Feig BW; Ames FC; Hortobagyi GN
Ann Surg Oncol; 2006 Jun; 13(6):776-82. PubMed ID: 16614878
[TBL] [Abstract][Full Text] [Related]
54. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
Harvey PW
J Appl Toxicol; 2005; 25(3):179-83. PubMed ID: 15856525
[TBL] [Abstract][Full Text] [Related]
55. Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk.
Lewy H; Haus E; Ashkenazi IE
Chronobiol Int; 2007; 24(2):365-81. PubMed ID: 17453854
[TBL] [Abstract][Full Text] [Related]
56. [Prolactin and cancer of the breast].
Marugo M; Giusti M; Bolognesi F; Reitano A
Boll Soc Ital Biol Sper; 1977 Apr; 53(8):675-8. PubMed ID: 907746
[No Abstract] [Full Text] [Related]
57. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy.
von Tempelhoff GF; Nieman F; Heilmann L; Hommel G
Clin Hemorheol Microcirc; 2000; 22(2):107-30. PubMed ID: 10831062
[TBL] [Abstract][Full Text] [Related]
58. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
59. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
60. [Dynamics of gonadotropins and prolactin in dysplasias and cancer of the breast].
Korolev VI; Skliar SIu; Ponomarev IN
Vrach Delo; 1988 Jan; (1):59-61. PubMed ID: 3363942
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
